Latest News
Avacta Inks SARS-CoV-2 Rapid Antigen Test Clinical Collaboration
7 August 2020 - - UK-based biotherapeutics and reagents developer Avacta Group plc (AIM: AVCT) has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test tha...
ViiV Healthcare Wins FDA Nod of Expanded Dovato Indication
7 August 2020 - - The US Food and Drug Administration approved Dovato (dolutegravir/lamivudine) as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral regimen in adults who are virologically suppressed (HIV-1...
Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by Blenrep FDA Approval
7 August 2020 - - The US Food and Drug Administration has approved GlaxoSmithKline's (LSE: GSK) Blenrep (belantamab mafodotin-blmf), an antibody-drug conjugate targeting B-cell maturation antigen that utilizes Seattle Genetics' proprietary ...
Pulse Biosciences Names van den Broek to Board of Directors
7 August 2020 - - US-based novel bioelectric medicine company Pulse Biosciences, Inc. (NASDAQ: PLSE) has appointed Richard van den Broek to its board of directors, the company said.

In connection with his appointment to the board, van de...
Levo Therapeutics Releases Disappointing Top-line Results from Phase 3 CARE-PWS Study of LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
7 August 2020 - - US-based biotechnology company Levo Therapeutics, Inc has released top-line results from the Phase 3 CARE-PWS clinical study evaluating LV-101 (intranasal carbetocin) for the treatment of PWS.

This syndrome is a comple...